Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

Cancer Immunology, Immunotherapy

Volumn 64, Issue 2, 2015, Pages 181-190

  Cui, Guanglin ^a,b,c   Qi, Haili ^a   Gundersen, Mona D ^c   Yang, Hang ^a   Christiansen, Ingrid ^c   Sørbye, Sveinung W ^c   Goll, Rasmus ^c   Florholmen, Jon ^c  

^a ZHENGZHOU UNIVERSITY   (China)

^b NORD UNIVERSITY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Adenoma carcinoma transition; Colorectal cancer; Interleukin 33; ST2

Indexed keywords

INTERLEUKIN 33; MESSENGER RNA; PROTEIN; ST2 PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CAPILLARY DENSITY; CLINICAL FEATURE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MICROSCOPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SPORADIC COLORECTAL CANCER; STROMA CELL; TUMOR MICROENVIRONMENT; VERY ELDERLY; ADENOMA; CANCER GRADING; COLORECTAL NEOPLASMS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSCRIPTION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84922433330     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1624-x     Document Type: Article

References (43)

1. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767
2. Leslie A, Carey FA, Pratt NR, Steele RJ (2002) The colorectal adenoma-carcinoma sequence. Br J Surg 89:845–860
3. Khosraviani K (1996) Colorectal adenoma-carcinoma sequence. Gut 39:342
4. Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12:375–391
5. Cacev T, Radosevic S, Krizanac S, Kapitanovic S (2008) Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29:1572–1580
6. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735–6741
7. Fantini MC, Pallone F (2008) Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 9:375–380
8. Choi JW, Liu H, Shin DH, Yu GI, Hwang JS, Kim ES, Yun JW (2013) Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics 13:2361–2374
9. Chung YC, Chang YF (2003) Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 50:1910–1913
10. Kang M, Edmundson P, Araujo-Perez F, McCoy AN, Galanko J, Keku TO (2013) Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas. BMC Cancer 13:91
11. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS (2008) Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 68:323–328
12. Krzystek-Korpacka M, Diakowska D, Kapturkiewicz B, Bebenek M, Gamian A (2013) Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett 337:107–114
13. Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, Florholmen J (2007) Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother 56:985–995
14. Cui G, Yuan A, Goll R, Vonen B, Florholmen J (2009) Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 58:1897–1905
15. Oliveira Frick V, Rubie C, Ghadjar P, Faust SK, Wagner M, Graber S, Schilling MK (2011) Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies. Tumour Biol 32:189–196
16. Pellegrini P, Berghella AM, Contasta I, Del Beato T, Adorno D (2006) The study of a patient’s immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. Cancer Biother Radiopharm 21:443–467
17. Liew FY (2012) IL-33: a Janus cytokine. Ann Rheum Dis 71(Suppl 2):i101–i104
18. Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, Lopez F, Gonzalez MJ, Quera R, Hermoso MA (2010) Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16:1097–1107
19. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 52:89–99
20. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y, Andoh A (2010) Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45:999–1007
21. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN, Lukic ML (2012) IL-33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunology 1:229–231
22. Eiwegger T, Akdis CA (2011) IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. Eur J Immunol 41:1535–1538
23. Schmieder A, Multhoff G, Radons J (2012) Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 60:514–521
24. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, Lin YS (2013) The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 231:180–189
25. Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, Yang DJ, Jiang YF (2012) Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res 40:1654–1661
26. Hu LA, Fu Y, Zhang DN, Zhang J (2013) Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev 14:2563–2566
27. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y (2011) Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 56:3596–3601
28. Musolino C, Allegra A, Profita M, Alonci A, Saitta S, Russo S, Bonanno A, Innao V, Gangemi S (2013) Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Heamatol 160:709–710
29. Seidelin JB, Rogler G, Nielsen OH (2011) A role for interleukin-33 in T(H)2-polarized intestinal inflammation? Mucosal Immunol 4:496–502
30. Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R (2006) Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Inv 66:249–259
31. Cui G, Koh TJ, Chen D, Zhao CM, Takaishi S, Dockray GJ, Varro A, Rogers AB, Fox JG, Wang TC (2004) Overexpression of glycine-extended gastrin inhibits parietal cell loss and atrophy in the mouse stomach. Cancer Res 64:8160–8166
32. Cui J, Xu G, Liu J, Pang Z, Florholmen J, Cui G (2013) The expression of non-mast histamine in tumor associated microvessels in human colorectal cancers. Pathol Oncol Res 19:311–316
33. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML (2014) Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 134:1669–1682
34. Kuchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H, Haraldsen G (2008) Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 173:1229–1242
35. Contasta I, Berghella AM, Pellegrini P, Adorno D (2003) Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 18:549–557
36. Marvie P, Lisbonne M, L’Helgoualc’h A, Rauch M, Turlin B, Preisser L, Bourd-Boittin K, Theret N, Gascan H, Piquet-Pellorce C, Samson M (2010) Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 14:1726–1739
37. Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M (2012) Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol 132:2593–2600
38. Byrne SN, Beaugie C, O’Sullivan C, Leighton S, Halliday GM (2011) The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol 179:211–222
39. Seltmann J, Werfel T, Wittmann M (2013) Evidence for a regulatory loop between IFN-gamma and IL-33 in skin inflammation. Exp Dermatol 22:102–107
40. Gschwantler M, Kriwanek S, Langner E, Goritzer B, Schrutka-Kolbl C, Brownstone E, Feichtinger H, Weiss W (2002) High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics. Eur J Gastroenterol Hepatol 14:183–188
41. Ajdukovic J, Tonkic A, Salamunic I, Hozo I, Simunic M, Bonacin D (2010) Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology 57:1442–1444
42. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH (2010) IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 128:80–85
43. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM, Kwon YG (2009) Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 114:3117–3126